|
4小结
MMPs/TIMP在PVR发病过程中可能机制的研究中已取得了初步的进展，但对于每一种MMPs在PVR不同阶段，不同程度的表达相关关系，以及TIMP是如何活化及调控，等等问题还需要进一步的研究。以MMP/TIMP 系统靶向干预已取得一定进展,期待更特异、更安全的MMPs及其抑制剂的出现为PVR的治疗带来新的希望。
【参考文献】
1 Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of meta lloproteinases:structure,function,and biochemistry. Circ Res 2003;92 (8):827839
2 Fernandez CA, Butterfield C, Jackson G, et al. Structural and functional uncoupling of the enzymatic and angiogenic inhibitory activities of tissue inhibitor of metalloproteinase2 (TIMP2): loop 6 is a novel angiogenesis inhibitor.J Biol Chem 2003;278(42):4098940995
3栗映梅,申家泉.基质金属蛋白酶及其组织抑制因子与眼病的相关性研究进展.国际眼科杂志 2007;7(4):11351138
4黎晓新,王景昭.玻璃体视网膜手术学.北京:人民卫生出版社 2000:216218
5 Sethi CS, Bailey TA, Luthert PJ, et al. Matrix metalloproteinase biology applied to vitreoretinal disorders. Br J Ophthalmol 2000;84(6):654666
6孙晓东,张皙.细胞外基质及其调控与增殖性玻璃体视网膜病变.中国实用眼科杂志 1997;15(12):706710
7 Donnelly R, Collinson DJ, Manning G. Hypertension, matrix metalloproteinases and target organ damage. J Hypertens 2003;21(9):16271630
8 Zhang X, Sakamoto T, Hata Y, et al. Expression of matrix metalloproteinases and their inhibitors in experimental retinal ischemiaperfusion injury in rats. Exp Eye Res 2002;74(5):577584
9 Grisanti S, Guidry C. Transdifferentiation of retinal pigment epithelial cells from epithelial to mesenchymal phenotype. Invest 0phthalmol Vis Sci 1995;36(2):391405
10赵莺,柳林.视网膜色素上皮细胞在增生性玻璃体视网膜病变中的作用.国际眼科杂志 2003;3(3):5962
11 Sheridan CM, Occleston NL, Hiscott P, et al. Matrix metalloproteinases: a role in the contraction of vitreoretinal scar tissue. Am J Pathol 2001;159(4):15551566
12 Webster L, Chignell AH, Limb GA. Predominance of MMP 1 and MMP2 in the epiretinal and subretinal membranes of proliferative vitreoretinopathy. Exp Eye Res 1999;68(1):9198
13朱丹,赵明威,黎晓新,等. 增生性玻璃体视网膜病变增生膜再塑型机制的研究.中华眼底病杂志 2006;22(5):308312
14 Immonen I, Konttinen YT, Sorsa T, et al. Proteinases in subretinal fluid. Graefes Arch Clin Exp Ophthalmol 1996;234(2):105109
15 Symeonidis C, Diza E, Papakonstantinou E, et al. Expression of matrix metalloproteinases in the subretinal fluid correlates with the extent of rhegmatogenous retinal detachment. Graefes Arch Clin Exp Ophthalmol 2007;245(4):560568
16沈玺,叶纹.非手术方法治疗增生性玻璃体视网膜病变.国外医学眼科分册 2000;24(1):4248
17 Salzmann J, Limb GA, Khaw PT, et al. Matrix metalloproteinases and their natural inhibitors in fibrovascular membranes of proliferative diabetic retinopathy. Br J Ophthalmol 2000;84(10):10911096
18 Matsuo T, Okada Y, Shiraga F, et al. TIMP1 and TIMP2 levels in vitreous and subretinal fluid . Jpn J Ophthalmol 1998;42(5):377380
19冯学峰,惠延年,石一宁.实验性增殖性视网膜病变玻璃体内Ⅲ型前胶原的放射免疫测定.中华眼底病杂志 1998;14(1):4344
20 Scott KA, Wood EJ, Karran EH. A matrix metalloproteinase inhibitor which prevents fibroblastmediated collagen lattice contraction. FEBS Lett 1998;441(1):137140
21 Sheridan CM, Occleston NL, Hiscott P, et al. Matrix metalloproteinases: a role in the contraction of vitreoretinal scar tissue. Am J Pathol 2001;159 (4):15551566
22 GonzalezAvila G,Mendez D,Lozano D, et al. Role of retinal detachment subretinal fluid on extracellular matrix metabolism. Ophthalmologica 2004;218(1):4956
23 Ozerdem U, MachHofacre B, Keefe K, et al. The effect of prinomastat (AG3340), a synthetic inhibitor of matrix metalloproteinases, on posttraumatic proliferative vitreoretinopathy. Ophthalmic Res 2001;33(1):2023
24 Ozerdem U, MachHofacre B, Cheng L, et al. The effect of prinomastat (AG3340), a potent inhibitor of matrix metalloproteinases, on a subacute model of proliferative vitreoretinopathy. Curr Eye Res 2000;20(6):447453
25 Wong TT, Mead AL, Khaw PT. Matrix metalloproteinase inhibition modulates postoperative scarring after experimental glaucoma filtration surgery. Invest Ophthalmol Vis Sci 2003;44(3):10971103
26刘海霞,张文华,潘志强,等.基质金属蛋白酶抑制剂治疗碱烧伤后兔角膜融解的研究.中华眼科杂志 2002;38(9):539542
27朱丹,赵明威,黎晓新.GM6001预防dispase诱导的兔眼增生性玻玻璃体视网膜病变.眼科研究 2006;24(3):285288
28朱丹,赵明威,黎晓新.GM6001的玻璃体代谢及视网膜毒性作用的研究.内蒙古医学院学报 2006;28(1):15
29戴昳宁,王丽聪,张薇.基质金属蛋白酶1与组织型纤溶酶原激活因子联合治疗兔增生性玻璃体视网膜病变.中华眼底病杂志 2007;23(5):364365 上一页 [1] [2] [3] |
